KARVEA 75 mg FILM-COATED TABLETS

2. What you need to know before you take Karvea

Do not take Karvea

• if you are allergicto irbesartan or any of the other ingredients of this medicine (listed in section 6)
• if you are more than 3 months pregnant. (In any case, it is better to avoid taking this medicine during the first few months of pregnancy - see section "Pregnancy")
• if you have diabetes or kidney diseaseand are being treated with a blood pressure medicine containing aliskiren.

Warnings and precautions

Tell your doctor before taking Karvea and if any of the following apply to you:

• if you have excessive vomiting or diarrhea
• if you have kidney problems
• if you have heart problems
• if you are taking Karvea for diabetic kidney disease. In this case, your doctor may regularly perform blood tests, especially to measure potassium levels in case of impaired kidney function
• if you have low blood sugar levels (symptoms may include sweating, weakness, hunger, dizziness, trembling, headache, flushing, or pallor, numbness, rapid heartbeat), especially if you are being treated for diabetes

if you are going to have surgery(surgical procedure) or if you are going to be givenanesthetics

• if you are taking any of the following medicines used to treat high blood pressure:

• a medicine called an angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g., enalapril, lisinopril, ramipril), especially if you have kidney problems related to diabetes.

Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.

See also the information under the heading "Do not take Karvea".

If you are pregnant, think you may be pregnant, or plan to become pregnant, inform your doctor. Karvea is not recommended during the first few months of pregnancy (first trimester) and should not be taken after the third month of pregnancy, as it may harm your baby (see section "Pregnancy").

Children and adolescents

This medicine should not be used in children and adolescents as the safety and efficacy have not been fully established.

Taking Karvea with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Your doctor may need to change your dose and/or take other precautions:

If you are taking an ACE inhibitor or aliskiren (see also the information under the headings "Do not take Karvea" and "Warnings and precautions").

You may need to have blood tests if you are taking:

• potassium supplements
• potassium-sparing diuretics (a type of diuretic)
• lithium-containing medicines
• repaglinide (a medicine used to reduce blood sugar levels)

If you are using a type of painkiller known as non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.

Taking Karvea with food and drink

Karvea can be taken with or without food.

Pregnancy and breastfeeding

Pregnancy

Inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will advise you to stop taking Karvea before you become pregnant or as soon as you know you are pregnant, and will recommend an alternative blood pressure medicine. Karvea should not be taken during the first few months of pregnancy and should not be used after the third month of pregnancy, as it may harm your baby.

Breastfeeding

Inform your doctor if you are breastfeeding or plan to start breastfeeding. Your doctor may decide to give you a different treatment that is more suitable if you want to breastfeed, especially for newborns or premature babies.

Driving and using machines

Karvea is unlikely to affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.

Karvea contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.

Karvea contains sodium. This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".

3. How to take Karvea

Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.

Method of administration

Karvea is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). Karvea can be taken with or without food. Try to take your daily dose at the same time each day. It is important to continue taking this medicine until your doctor tells you to stop.

• Patients with high blood pressure

The usual dose is 150 mg once daily (two tablets a day). Depending on the response to blood pressure, this dose may be increased to 300 mg once daily (four tablets a day).

• Patients with high blood pressure and type 2 diabetes with kidney damage

In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney damage is 300 mg once daily (four tablets a day).

Your doctor may advise a lower dose, especially when starting treatment, in certain patients, such as those on hemodialysisor over 75 years of age.

The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.

Use in children and adolescents

Karvea should not be given to children under 18 years of age. If a child swallows several tablets, contact your doctor immediately.

If you take more Karvea than you should

If you accidentally take too many tablets, contact your doctor immediately.

If you forget to take Karvea

If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

However, some of these side effects can be serious and may require medical attention.

As with similar medicines, rare cases of skin allergic reactions (rash, urticaria) and localized swelling (in the face, lips, and/or tongue) have been reported in patients treated with irbesartan. If you think you may have a reaction of this type or experience difficulty breathing, stop takingKarveaand seek medical attention immediately.

The following side effects have been reported:

Very common: may affect more than 1 in 10 people

Common: may affect up to 1 in 10 people

Uncommon: may affect up to 1 in 100 people

The following side effects have been reported in clinical trials in patients treated with Karvea:

• Very common (may affect more than 1 in 10 people): if you have high blood pressure and type 2 diabetes with kidney damage, blood tests may show high potassium levels.

• Common (may affect up to 1 in 10 people): dizziness, nausea/vomiting, fatigue, and blood tests may show high levels of an enzyme that measures muscle and heart function (creatine kinase). In patients with high blood pressure and type 2 diabetes with kidney damage, dizziness (especially when standing up), low blood pressure (especially when standing up), muscle or joint pain, and decreased levels of a protein present in red blood cells (hemoglobin).

• Uncommon (may affect up to 1 in 100 people): rapid heartbeat, flushing, cough, diarrhea, indigestion/heartburn, sexual dysfunction (sexual function disorders), and chest pain.

Since the marketing of Karvea, the following side effects have been reported:

Frequency not known: cannot be estimated from the available data

The following side effects have been reported: feeling dizzy, headache, altered taste, ringing in the ears, muscle cramps, muscle or joint pain, decreased number of red blood cells (anemia - symptoms may include tiredness, headaches, difficulty breathing when exercising, dizziness, and paleness), reduced number of platelets, abnormal liver function, high potassium levels in the blood, impaired kidney function, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), severe allergic reactions (anaphylactic shock), and low blood sugar levels. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Karvea

Keep out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.

Do not store above 30°C.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Karvea contains

• The active substance is irbesartan. Each Karvea 75 mg tablet contains 75 mg of irbesartan.
• The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, colloidal silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, and carnauba wax. See section 2 "Karvea contains lactose".

Appearance and packaging

Karvea 75 mg film-coated tablets are white or almost white, biconvex, and oval-shaped, with a heart-shaped indentation on one side and the number 2871 engraved on the other side.

Karvea 75 mg tablets are available in blister packs of 14, 28, 30, 56, 84, 90, or 98 film-coated tablets. They are also available in packs of 56 x 1 film-coated tablet containing unit-dose blisters for hospital use.

Not all pack sizes may be marketed.

Marketing authorization holder

sanofi-aventis groupe, 54 rue La Boétie, F-75008 Paris, France

Manufacturer

SANOFI WINTHROP INDUSTRIE, 1, rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc Cedex, France

SANOFI WINTHROP INDUSTRIE, 30-36 Avenue Gustave Eiffel, BP 7166, F-37071 Tours Cedex 2, France

For further information, contact the local representative of the marketing authorization holder.

Date of last revision of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/